Migraine is a clinical condition characterized by severe headaches and symptoms like sensitivity to smell, nausea, and more. The headaches are typically localized to one side of the head and can vary in duration and intensity with each episode. Migraine drugs are specifically designed to alleviate the pain and associated symptoms of migraine headaches. These medications aim to provide relief by targeting the underlying causes and mechanisms of migraines, offering patients a means to manage and reduce the impact of these debilitating headaches.
According to Data Bridge Market Research, the Migraine Drugs Market is expected to grow with a CAGR of 15.75% in the forecast period of 2022 to 2029.
“The increase in the prevalence of migraine drives the market”
The rising prevalence of migraines is a significant driver for the growth of the migraine drug market. Migraine, a neurological disorder characterized by recurrent headaches, affects a substantial portion of the global population. As awareness and diagnosis of migraines increase, there is a growing demand for effective treatments. This has led to the development of various migraine drugs, including both preventive and acute treatments. The expanding market for migraine drugs is driven by the need for relief and improved quality of life for individuals suffering from migraines.
What restraints the growth of the migraine drugs market?
“Side effects associated with migraine drugs impede the market”
The side effects of these medications restrain the growth of the migraine drug market. While migraine drugs aim to provide relief, they can also adversely affect some individuals. Common side effects may include nausea, dizziness, drowsiness, and even more severe reactions in some cases. These side effects can deter patients from seeking or continuing treatment, leading to decreased market growth. The challenge for pharmaceutical companies is to develop safer and more tolerable migraine drugs to address these concerns and promote market expansion.
Segmentation: Migraine Drugs Market
The migraine drugs market is segmented on the basis of product type, route of administration, distribution channel, and end-users.
- On the basis of product type, the migraine drugs market has been segmented into acute migraine treatment and preventive migraine treatment.
- On the basis of route of administration, the migraine drugs market has been segmented into oral, injection, and others.
- On the basis of distribution channel, the migraine drugs market has been segmented into hospital pharmacy, retail pharmacy and online pharmacy.
- On the basis of end-users, the migraine drugs market has been segmented into hospitals, homecare, specialty clinics, and others.
Regional Insights: North America Dominates the Migraine Drugs Market
North America dominates the migraine drugs market owing to the research and development activities in the pharmaceutical sector within the region have contributed to the growth of the migraine drugs market. Ongoing advancements and innovations in drug development have led to the introduction of new and improved migraine treatments, expanding the market's potential.
Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 due to the rise in demand for better healthcare facilities in the region has spurred the growth of the migraine drugs market. As healthcare standards improve, an increased focus is on providing effective treatments for conditions like migraines, driving the market's expansion.
To know more about the study visit, https://www.databridgemarketresearch.com/jp/reports/global-migraine-drugs-market
The Prominent Key Players Operating in the Migraine Drugs Market Include:
- Abbott (U.S.)
- Aegis Therapeutics, LLC (U.S.)
- Aerial BioPharma LLC (U.S.)
- Alder BioPharmaceuticals Inc. (U.S.)
- Amgen Inc. (U.S.)
- Astellas Pharma India Private Limited (U.K.)
- AstraZeneca (U.K.)
- Dr. Reddy's Laboratories Ltd. (India)
- Johnson & Johnson Services, Inc. (U.S.)
- Eisai Co., Ltd. (Japan)
- Eli Lilly and Company (U.S.)
- Bayer AG (Germany)
- CoLucid (U.S.)
- KOWA Pharmaceuticals America, Inc. (U.S.)
- Luitpold Pharmaceuticals, Inc. (U.S.)
- Klaria (Sweden)
- Ethypharm (France)
- INTELGENX CORP. (Canada)
- Global Information, Inc. (Japan)
- LePro PharmaCompass OPC Private Limited (India)
- Zogenix, Inc. (U.S.)
- WINSTON PHARMACEUTICALS, Inc. (U.S.)
- Valeant (Canada)
- TG Therapeutics, Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Horizon Pharma plc. (Ireland)
- Aralez Pharmaceuticals Inc. (Canada)
- RedHill (Israel) Pfizer Inc. (U.S.)
- OptiNose US, Inc. (U.S.)
- Merck & Co. (U.S.)
- Suda Ltd. (Australia)
Above are the key players covered in the report, to know about more and exhaustive list of migraine drugs market companies contact, https://www.databridgemarketresearch.com/jp/contact
Research Methodology: Global Migraine Drugs Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
